Portfolio

TAI Diagnostics

Monitoring the Health of Transplanted Organs

TAI Diagnostics, Inc. is a biotechnology company focused on providing a non-invasive and highly sensitive diagnostic test to monitor the health of transplanted organs in patients who have received solid organ transplants.

Rejection is the major cause of transplant failure, and transplant recipients require lifelong rejection surveillance to guide modulation of immunosuppressant dosage and frequently require clinical interventions to improve organ function.

TAI Diagnostics first test offering, myTAIHEART, is for cardiac transplant patients. The current gold standard surveillance test for these patients is the endomyocardial biopsy, a procedure that is invasive, subject to sampling error, and expensive for both the patient and the healthcare system.

myTAIHEART was designed to meet these clinical needs. The assay requires only a small blood sample and is available to adult and pediatric patients rapidly post-transplant. The myTAIHEART Assay has a high degree of sensitivity and specificity, a rapid turnaround time, and can be offered at a very competitive price point.

Somna Therapeutics

Relief from Reflux

Somna Therapeutics provides medical devices for the treatment of acid reflux diseases. It offers Reflux Band^TM, a non-pharmacologic, wearable device that prevents reflux into the larynx, pharynx, and lungs. The Reflux Band^TM is founded on scientific and clinical research conducted over 20 years by a leading gastroenterologist at the Medical College of Wisconsin. Clinical studies show 86% of patients had a successful outcome with significant reduction in acid reflux symptoms after two weeks while physicians reported being satisfied with the Reflux Band 92% of the time.

Acid reflux represents a huge healthcare expense, with more than 64 million American adults reporting chronic acid reflux or regurgitation symptoms each year.  Somna offers the first and only solution that does not require surgery or drugs to treat reflux. The Reflux Band^TM was recently FDA-cleared for sale over-the-counter (OTC) and available online at RefluxBand.com.

POPS! Diabetes Care

Your Liberating Digital Health Solution

POPS! Diabetes Care system is the more portable, simpler, and liberating way for people with diabetes to manage their condition. You can manage your diabetes in your own hands.  Your phone app coaches you, without judgment, and seamlessly pairs to your portable and discrete glucose monitor to create a simple user experience to help you meet your personal goals.

More than 30 million Americans have diabetes, and another 84 million have prediabetes, which often leads to diabetes within five years.  The American Diabetes Association estimates that the total costs of diabetes in the US was $327 billion in 2017, one of the world’s largest healthcare expenses. POPS! offers a new approach to diabetes management – a virtual care solution that liberates people with diabetes through a positive user experience, encouraging sustained use and the opportunity to drive better outcomes and lower healthcare costs.